SERPINA3 is a key modulator of HNRNP-K transcriptional activity against oxidative stress in HCC

Eunkyong Ko, Jong-Hee Kim, Jong Woo Bae, Jeesoo Kim, Sung-Gyoo Park, Guhung Jung

Abstract

Most studies about serpin peptidase inhibitor, clade A member 3 (SERPINA3) have been limited to its inhibitory functions and mechanisms. Herein, we report a novel role of SERPINA3 in transcriptional regulation of HCC progression-related genes. Among 19 selected genes through HCC cell isolation system based on telomere length, microarray analyses, and cell-based studies, SERPINA3 was the strongest determinant of increases in telomere length, HCC cell proliferation, survival, migration, and invasion. We also found that SERPINA3 strongly interacted with heterogeneous nuclear ribonucleoprotein K (HNRNP-K) under H2O2 exposure, and the oxidation-elicited SERPINA3-HNRNP-K complex enhanced the promoter activities and transcript levels of a telomere-relating gene (POT1) and HCC-promoting genes (UHRF1 and HIST2H2BE). Intriguingly, the inhibition of SERPINA3 oxidation rendered the transcriptional activity of the SERPINA3-HNRNP-K complex suppressed. Moreover, the co-immunoprecipitated HNRNP-K with SERPINA3 quantitatively correlated with not only the level of SERPINA3 oxidation but also the level of POT1, UHRF1, and HIST2H2BE transcripts and telomere length in HCC tissues. Therefore, the upregulated transcriptional activity of HNRNP-K mediated by SERPINA3 promotes HCC cell survival and proliferation and could be an indicator of poor prognosis for HCC patients.

1. Introduction

Liver hepatocellular carcinoma (HCC) is the second leading cause of cancer-related death worldwide, with a mortality rate exceeding 35% in Asia for patients ≥50 years of age and approximately 5-year survival rates of 15% in the United States, and 12% in Europe [1,2]. The incidence and mortality rates of HCC are expected to increase steadily [1,2]. Despite the increasing number of treatment options against advanced HCC (GII and GIII HCC), the selection of a suitable treatment strategy can be difficult [1,2]. This is not only because HCC is a very heterogeneous disease induced by multiple underlying etiologies, molecules, and signaling pathways, but also the drug-mediated hepatotoxicity can occur during treatment [1,2]. Major risk factors for HCC such as the chronic viral infections (hepatitis B or C virus), alcoholic hepatitis, and non-alcoholic fatty liver disease increase the level of reactive oxygen species (ROS) [3,4]. The ROS levels are strongly correlated with the progression of human HCC from early-to-advanced-grade [5,6]. HCC cell lines under the elevated ROS environment also show similar malignant phenotypes with the advanced HCC tissues [5–7]. These phenotypes encompass the decreased level of antioxidant enzymes [5,7], the increased epithelial-to-mesenchymal transition (EMT) [5], the increased activity of cell invasion and migration [5–7], the increased expression of telomerase reverse transcriptase (TERT), the enhanced telomerase activity, and the elongated telomere length [6].

It has been known that the heterogeneous nuclear ribonucleoprotein-K (hnRNPK) (hnRNPK) was upregulated in human HCC tumor tissues, compared to the corresponding non-tumorous tissues [8]. Similarly, the upregulated hnRNPK expression has been correlated with poor clinical outcomes and HCC malignancy [8]. The hnRNPs comprise a large family of proteins that play important roles in telomere biogenesis, DNA repair, and the regulation of expression at both the transcriptional and translational levels [9,10]. The hnRNPK, which is one of the most extensively studied hnRNP family members, recognizes the C-rich binding motif in gene regulatory and telomeric DNA [8–10]. It has been suggested that the binding of hnRNPK to the specific C-rich motifs could be essential in diverse signal transduction pathways, including...
growth regulation and cellular transformation [8,9], but the modulatory mechanisms regarding the hnRNP-K transcriptional activity in HCC still remain unclear.

Recently we reported that the serpin peptidase inhibitor, clade A member 3 (SERPINA3) was a transcriptional activator of PI3Kε expression in HCC progression [11]. ROS induced oxidative modification of specific residues in SERPINA3, thereby leading to PI3Kε signaling activation and HCC proliferation [11]. In this paper, we provide the mechanism for the SERPINA3-mediated transcriptional expression of genes responsible for HCC progression. SERPINA3 modulates hnRNP-K transcriptional activity through interaction with the HNRNP-K-protein-interactive (KI) domain of hnRNP-K in human HCC cell lines. For the interaction of SERPINA3 with hnRNP-K through KI domain, the ROS-dependent oxidation of SERPINA3 protein was found to be the prerequisite step. Moreover, the strong interaction of SERPINA3 with HNRNP-K promoted HCC cell survival and proliferation via regulating the gene transcriptions involved in telomere-maintenance and HCC malignancy. Thus, blockade of the association of SERPINA3 with HNRNP-K protein could be valuably used for HCC therapy.

2. Materials and methods

All detail experimental procedures have been described in the supplementary information. Please see details in SI Appendix.

3. Results

3.1. Identification of a novel role of SERPINA3 as a molecular linker between telomere maintenance factors and HCC tumorigenic factors

We previously documented that H2O2 treatment induced a telomere elongation and cell invasion [5,6,12] in HCC cells. In this study, to further examine the molecular linkage between telomere maintenance and cell invasion, we isolated cells with H2O2-mediated long telomeres (cells with top 6% of telomere intensity) and short telomeres (cells with bottom 66% of telomere intensity), respectively (Fig. 1A). HCC cells with long telomeres showed a higher invasion ability, as well as better in vivo tumor growth compared to the short telomere-containing cells (Fig. 1B and C). While the BIRR1532, a telomerase inhibitor, alone was not enough to shorten telomeres in HCC cell lines even after two-weeks (SI Appendix, Fig. S1), co-treatment with BIRR1532 and H2O2 facilitated the telomere shortening (SI Appendix, Fig. S1). This is consistent with the previous reports describing severe telomeric damage caused by H2O2 in HCC cells under telomerase inhibition [6]. After the induction of telomere shortening, HCC cells with long telomeres also exhibited decreased telomere length, cell migration, invasion, and in vivo tumor growth (Fig. 1B and C). Taken together, these results suggest that the telomere length positively associates with the HCC cell migration, invasion, and tumor growth, and the telomere machinery may be linked with the HCC-progression factors.

To identify the regulatory factor(s) which links the telomere maintenance factors with HCC-progression factors, we analyzed the microarray data of HCC cells with long and short telomeres (GEO accession number GSE114004), and found that Uhrf1, Hist2h2be, Arl14, Ptgs2, Myl1p, Hint3, Ptger4, Uccg, Znf212, Hsd3b1, Tmem27, and Sult2a1 were upregulated, while Serpina3, Mtix, Scl6a14, Ahsg, Itih2, Orm1, and Orm2 were downregulated in long telomere-containing HCC cells (Fig. 1D). To determine the subcellular localization of the candidate proteins, the candidates were tagged with EGFP at the individual N-terminus and expressed in Huh7 cells (Fig. 1D and E; SI Appendix, Fig. S2). Among the 19 candidates, 10 genes (Serpina3, Uhrf1, Hist2h2be, Arl14, Ptgs2, Mtix, Scl6a14, Myl1p, Ahsg, and Hint3) were frequently distributed in telomeres after H2O2 treatment (Fig. 1E; SI Appendix, Fig. S2). Approximately 90–95% of HCC tumor cells showed telomerase-dependent telomere maintenance [13–15]. Telomere maintenance is required for evading the cellular crisis induced by the shortened telomeres during liver cirrhosis [3,4,6]. Thus, we hypothesized that telomere maintenance might be essential for HCC progression and the genes, which represent an altered frequency of telomere localization under H2O2 treatment, could affect telomere maintenance-mediated HCC tumor progression.

We next dissected the roles of 10 selected genes based on the H2O2 treatment dependent changes in the telomere localization frequency using Ingenuity Pathway Analysis (IPA) (SI Appendix, Fig. S3A). The IPA of differentially expressed genes including the 10 selected genes, predicted the prominent function of tumor progression signaling networks (SI Appendix, Fig. S3A). We next quantified telomere lengths, the transcript levels of telomerase subunits, and invasion-associated genes in HCC cells during gene overexpression (Fig. 1F; SI Appendix, Figs. S3B and S3C). In addition, we measured cell growth rates, cell migration and invasion abilities, and the high-dose chemical-mediated mortality rates in the HCC cells following gene overexpression (Fig. 1F; SI Appendix, Figs. S3B and S3C). Overall, we concluded that SERPINA3 was the most determining gene candidate responsible for telomere maintenance, HCC cell proliferation, survival, migration, and invasion (Fig. 1F; SI Appendix, Figs. S3B and S3C).

3.2. Involvement of SERPINA3 in HNRNP-K’s transcriptional activity

Serpina3 activity to promote both telomere elongation and HCC progression was upregulated under H2O2 exposure (Fig. 1). To disclose the underlying mechanism of SERPINA3-mediated telomere maintenance and HCC malignancy, we aimed to identify interacting partners with SERPINA3 under H2O2 treatment in HCC cells. Co-immunoprecipitation (co-IP) and LC-MS/MS analyses showed 21 protein candidates for SERPINA3 interactome (Fig. 2A; SI Appendix, Fig. S4). Via label-free quantification analysis of co-IP LC-MS/MS data against those from the mock- and H2O2-treated Huh7 cells, we further identified HNRNP-K as an H2O2-sensitive binding partner of SERPINA3 (Fig. 2A and B; SI Appendix, Fig. S4). The KI domain corresponding to amino acids 210–340 in HNRNP-K was the binding part to SERPINA3 (Fig. 2B).

We previously reported the increased oxidation levels of methionine residues including M137, M141, M284, and M290 in SERPINA3 induced by H2O2 treatment and the lack of oxidation levels induced by mutating the methionine to leucine [11]. H2O2 increased the nuclear levels of both SERPINA3 and HNRNP-K proteins (Fig. 2C left) and induced the strong association of SERPINA3 with HNRNP-K in HCC cells (Fig. 2C right). In particular, the SERPINA3 variant exhibiting low oxidation levels markedly failed to coimmunoprecipitate with HNRNP-K (Fig. 3A). To determine whether the oxidation-defective SERPINA3 influenced HNRNP-K transcription activity, we compared expression levels of protection of telomeres 1 (POT1), which is the target gene of the transcription factor, HNRNP-K [16], between HCC cells, following overexpression of the SERPINA3 WT and SERPINA3 oxidation-defective variant (Fig. 3B left). The promoter activity and transcription level of POT1 was reduced by the SERPINA3 oxidation variant (Fig. 3B left). The promoter activity and transcription level of PI3Kδ, which was changed by SERPINA3 expression in regard to transcription level [11], was also decreased by the oxidation variant (Fig. 3B middle left). Based on data showing that SERPINA3 only influenced the expressions of Uhrf1 and Hist2h2be (SI Appendix, Figs. S5 and S6) among the 19 genes selected in Fig. 1 and SI Appendix, Figs. S2–S3, we also tested the effect of the SERPINA3 oxidation defect on Uhrf1 and Hist2h2be expressions. SERPINA3 oxidation variant decreased promoter activity and transcription level of Uhrf1 and Hist2h2be (Fig. 3B middle right and right). Accordingly, oxidation of SERPINA3 is responsible for the POT1, Uhrf1, Hist2h2be, and PI3Kδ transcription levels in HCC cells.

We next determined that the transcriptional repression effect by the SERPINA3 oxidation defect involved a blockade of HNRNP-K activity. To examine the effect of this defect by the removal of endogenous activity, we established HCC cell lines stably expressing the SERPINA3
oxidation-defective variant plasmid, which is not degraded by SERPINA3 siRNA, and then administered SERPINA3 siRNA to the stable cell lines. The SERPINA3 deficiency using SERPINA3 siRNA remarkably decreased POT1, UHRF1, HIST2H2BE, and PI3Kδ transcription levels in the HCC cell lines stably expressing SERPINA3 oxidation-defective mutant (Fig. 3C). Similarly, siRNA-mediated HNRNP-K silencing...
significantly diminished transcription levels of the above-mentioned genes in the stable cell lines and human primary HCC cells (Figs. 3C and SI Appendix, Fig. S7A). This indicates that SERPINA3 functions in oxidized form to enable the transcriptional activity of HNRNP-K. Overall, these results suggested that decrease in oxidatively-modified SERPINA3 weakens the interaction between SERPINA3 and HNRNP-K and results in transcriptional downregulation of genes that are influenced by the SERPINA3-HNRNP-K complex.

3.3. Action of SERPINA3-HNRNP-K complex in transcriptional activation of POT1, UHRF1, and HIST2H2BE genes

To address the mechanism of action of the oxidized-SERPINA3 in regulation of POT1, UHRF1, and HIST2H2BE transcription, we performed the ChIP assay using HCC cells stably expressing SERPINA3 WT or the oxidation-defective variant. We found that the impaired oxidation of the SERPINA3 protein abolished the binding of SERPINA3 to the regulatory DNA in the POT1, UHRF1, and HIST2H2BE genes (Fig. 4A). We next determined whether SERPINA3 and HNRNP-K co-occupy the
same regions as the regulatory DNA in POT1, UHRF1, and HIST2H2BE genes, and found that SERPINA3 formed a complex with HNRNP-K on the regulatory DNA in these genes (Fig. 4B). While H$_2$O$_2$ induced a marked increase in the binding of HNRNP-K coimmunoprecipitated with SERPINA3 on these regulatory DNA, the ROS scavenger reagent N-acetylcysteine (NAC) abolished the H$_2$O$_2$-mediated binding of the SERPINA3-HNRNP-K complex (Fig. 4B). These results suggest that SERPINA3 that was oxidatively modified by H$_2$O$_2$ treatment increased the binding of the HNRNP-K-SERPINA3 complex in regulatory DNAs in POT1, UHRF1, and HIST2H2BE genes.

We next determined the effect of the SERPINA3 oxidation defect on the HNRNP-K binding to the regulatory DNA in POT1, UHRF1, and HIST2H2BE genes. ChIP data revealed that SERPINA3 oxidation impairment induced a sharp reduction in HNRNP-K binding to these regulatory DNA (Fig. 4C). This data indicated that the impaired oxidation on SERPINA3 limits the function of HNRNP-K as a transcriptional regulator. Further, we showed that the oxidation-defective SERPINA3 mutant displayed decreased telomere lengths, invasion ability, and cell viability as well as increased Caspase-3/7 activity (Fig. 4D). This is consistent with the observation of siRNA-mediated
HNRNP-K silencing in human primary HCC cells (SI Appendix, Fig. S7B). Collectively, these results suggest that oxidatively-modified SERPINA3 interact with HNRNP-K, which results in the up-regulation of POT1, UHRF1, and HIST2H2BE promoter activities and their transcription, thereby promoting HCC cell telomere elongation, invasion, proliferation, and survival.

3.4. SERPINA3-HNRNP-K complex as the target in the treatment of liver tumor

The SERPINA3 oxidation-defective mutation interfered with HNRNP-K binding to SERPINA3 and then inhibited HNRNP-K transcriptional activity (Figs. 3 and 4). We administered subcutaneous
Fig. 5A and intrahepatic injections (Fig. 5B) of Huh7 cells stably expressing SERPINA3 oxidation-defect to immunodeficient mice and tested whether the SERPINA3 oxidation-impairment inhibited tumor growth in vivo. Notably, we showed that SERPINA3 oxidation-defect decreased growth of subcutaneous (Fig. 5A) and liver tumors (Fig. 5B top). Moreover, the SERPINA3 oxidation-defect reduced the number of liver nodules, the mRNA levels of UHRF1, HIST2H2BE, and POT1, and telomere lengths (Fig. 5B bottom). Similar phenotypes were observed in the case of HNRNP-K knock-down through siRNA administration (Fig. 5A and B); supporting data showed that the SERPINA3-HNRNP-K complex acts as a transcriptional regulator (Figs. 3 and 4). Together, our results indicate that oxidative-modification of SERPINA3 is critical for the functioning of the SERPINA3-HNRNP-K complex as a transcriptional regulator in liver tumor progression. Furthermore, the increased association of SERPINA3 with HNRNP-K could promote malignant liver progression by modulating the expression of genes involved in HCC malignancy and telomere maintenance (Fig. 5C).

In human GIII HCC tissues, protein expression levels of SERPINA3, HNRNP-K, UHRF1, HIST2H2BE, and POT1 were higher than those in paired non-tumor tissues (Fig. 6A). SERPINA3 and HNRNP-K proteins were observed to be more distributed in the nuclei of GIII HCC tissues (Fig. 6A), supporting the transcriptional regulator activity of the SERPINA3-HNRNP-K complex (Figs. 3–5). We next analyzed the correlation between the levels of the oxidized-SERPINA3 protein and the amount of communoprecipitated HNRNP-K with SERPINA3 in GII and GIII HCC tissues (Fig. 6B and C). Linear regression analysis revealed a significant positive correlation between the oxidized-SERPINA3 levels and the SERPINA3-HNRNP-K complex levels (Pearson correlation coefficient: R = 0.8457; 95% confidence interval (CI) = 0.7864 to 0.8805; p < 0.0001, Fig. 6C). The high amount of communoprecipitated HNRNP-K with SERPINA3 was significantly associated with the high mRNA levels of UHRF1, HIST2H2BE, and POT1, and longer telomeres (Fig. 6D). Moreover, HCC patients with a high level of the SERPINA3-HNRNP-K complex showed significantly frequent HCC recurrence compared to those with low level of the complex (Hazard ratio = 10.36, 95% CI = 3.289 to 32.64, p < 0.0001; Fig. 6E). This result suggests that the strong interaction between SERPINA3 and HNRNP-K is a poor prognostic indicator of HCC. Next, we checked whether the upregulation of genes activated by recruitment of HNRNP-K to the gene loci, of which SERPINA3 binding to HNRNP-K can increase its efficiency, is related to HCC patient's survival using The Cancer Genome Atlas (TCGA) data. In agreement to our results, patients with high UHRF1 expression showed poor survival (Fig. S8).

4. Discussion

Oxidative modification induced by ROS alters the stability and function of proteins [17,18]. ROS triggers several signal transduction pathways through the oxidation modification of protein kinases and tyrosine phosphatases, including protein kinase C and phosphatase and tensin homolog deleted on chromosome 10 (PTEN) in tumorigenesis [19–21]. ROS also incrementally affects nuclear localization and the affinity of regulatory DNA-interaction of transcription factors, such as nuclear factor kappa B, p53, activating protein-1, and protein-disulfide...
Fig. 6. High-amount of coimmunoprecipitated HNRNP-K with SERPINA3 is associated with high levels of UHRF1, HIST2H2BE, and POT1 expressions as well as with high HCC recurrence in human HCC tissues. (A) Representative immunohistochemical staining of SERPINA3, HNRNP-K, UHRF1, HIST2H2BE, and POT1 in GII and GIII HCC tumor samples and non-tumor samples. (B, C) Immunoprecipitation (IP) using anti-SERPINA3 antibodies followed by immunoblotting analyses using antibodies against HNRNP-K in GII and GIII HCC tissue lysates (B), and correlation analysis between the oxidized-SERPINA3 and the amount of coimmunoprecipitated HNRNP-K with SERPINA3 determined by linear regression (C). n = 48 (D, E) Median mRNA levels of UHRF1, HIST2H2BE, and POT1, and median telomere length (D) and recurrence-free survival rates (E) in GII and GIII HCC tissues with low- and high-amount of coimmunoprecipitated HNRNP-K with SERPINA3 (n = 47). Horizontal bars indicate median values. IP, immunoprecipitation; IB, immunoblot; GII, Grade-II; GIII, Grade-III; R, Pearson correlation coefficient; HCC, hepatocellular carcinoma.
Serine protease inhibitors (SERPIN, also known as serine-type endopeptidase inhibitors) are a functionally diverse family of proteins with highly evolutionarily conserved structure from prokaryotes to placental mammals [25]. Encoded by a member of the SERPIN gene family, SERPINA3 has been known to be increased in plasma during proteolysis induced by infection, surgery, and tissue injury based on several reports dissecting the protein interactome in which SERPINA3 participates [26–30]. In some prokaryotes, reduction–oxidation reactions stabilize SERPIN protein but do not influence its protease inhibitory mechanism, suggesting another role of SERPINA3 than as a serine protease inhibitor [31]. Our current findings demonstrate the role of SERPINA3 as a novel transcriptional regulator of HCC progression, irrespective of the conventional role of SERPINA3 as a protease inhibitor.

Telomeres often form structures, such as T-loop, to protect it from DNA damage and to regulate telomere length [32]. One of the shelterin proteins, POT1 is an evolutionarily conserved telomere-binding protein that is essential in T-loop structure and telomere maintenance [33]. POT1 reportedly modulates telomere length by binding to a 3’ single-strand overhang telomeric DNA [34,35]. Importantly, its deficiency causes telomere loss and damage, genomic instability, and cell death [32]. Similarly, tumor cells overexpressing POT1 display telomere elongation, while inhibition of POT1 decreases telomere length [34,35]. Several papers have reported the positive association of POT1 expression and tumorogenesis in human cancers [26,37]. Here, we showed that POT1 transcription elicted by the SERPINA3-HNRP-K complex induced telomere elongation. We also showed that the SERPINA3-HNRP-K complex increased UHRF1 and HIST2H2BE transcriptional levels. UHRF1 functions as a regulator of DNA methylation and its overexpression drives HCC progression [38]. HIST2H2BE is a replication-independent histone variant [39] and to our knowledge, until now, there has been no functional study on HCC-associated HIST2H2BE. Our data and prior data from the TCGA [40] and GENT [41] databases show that HCC tumors have high mRNA levels of POT1, UHRF1, and HIST2H2BE compared with non-tumors. Moreover, we observed enhanced cell growth, EMT-promoting gene expression, migration, and invasion through UHRF1 and HIST2H2BE. Collectively, these results suggest that HNRP-K increases POT1, UHRF1, and HIST2H2BE transcription via the ROS-mediated interaction between SERPINA3 and HNRP-K in malignant HCC. SERPINA3 mRNA levels were reported to be lower in HCC tumors compared with non-tumors [42]. We also observed lower SERPINA3 mRNA levels in HCC cells with long telomeres relative to those with short telomeres. Notably, HCC tumors and HCC cells with long telomeres displayed higher SERPINA3 protein levels, suggesting that SERPINA3 activity is determined by the level of SERPINA3 protein, rather than by the SERPINA3 transcription level. These results suggest that SERPINA3 protein oxidation induced by ROS contributes to liver malignancy.

In conclusion, we screened for genes that were essential for telomere maintenance, cell migration and invasion, and cell proliferation in HCC, and identified the novel function of the SERPINA3-HNRP-K complex as the elevated ROS-promoted transcriptional regulator. Thus, the inhibition of interaction between SERPINA3 and HNRP-K possibly via the use of a non-toxic reductant that prevent the oxidation of SERPINA3 or a specific inhibitor of SERPINA3-HNRP-K interaction could block HCC survival and proliferation.

Acknowledgements

The biospecimens were provided by University of Korea and the Inje Biobank of Inje University Busan Paik Hospital, a member of Korea Biobank Network and the Seoul National University College of Medicine. We are deeply grateful to Dr. Eun Sun Jung, a pathologist at Seoul St. Mary’s Hospital for valuable advice and discussions on HCC grading and immunohistochemistry scoring, and Dr. Hyeky Cho, Dr. Yoon Jun Kim, and HCC patients at the Seoul National University College of Medicine for the fresh human livers. This study was supported by the Korea Healthcare Technology Research and Development Project of the Ministry of Health and Welfare of the Republic of Korea (HI14C2094 and HI16C1074) and Institute for Basic Science from the Ministry of Science, ICT and Future Planning of Korea (IBS-R008-D1).

Appendix A. Supplementary data

Supplementary data to this article can be found online at https://doi.org/10.1016/j.redox.2019.101217.

Conflicts of interest

The authors declare no conflict of interest.

References

[1] P.C. Valery, M. Laversanne, P.J. Clark, J.L. Pettick, K.A. McGlynn, F. Bray, Projections of Primary Liver Cancer to 2030 in 30 Countries Worldwide, Hepatology, 2017.
[2] C. Are, B. Meyer, A. Stack, H. Ahmad, L. Smith, B. Qian, T. Song, S. Chowdhury, Global trends in the burden of liver cancer, J. Surg. Oncol. 115 (2017) 591–602.
[3] H.B. El-Serag, K.L. Rudolph, Hepatocellular carcinoma: epidemiology and molecular carcinogenesis, Gastroenterology 132 (2007) 2557–2576.
[4] H. Cichoz-Lach, A. Michalak, Oxidative stress as a crucial factor in liver diseases, World J. Gastroenterol. 20 (2014) 8082–8091.
[5] S.O. Lim, J.M. Gu, M.S. Kim, H.S. Kim, Y.N. Park, C.K. Park, J.W. Cho, Y.M. Park, G. Jung, Epigenetic changes induced by reactive oxygen species in hepatocellular carcinoma: methylation of the E-cadherin promoter, Gastroenterology 135 (2008) 2128–2130 e2121-2128.
[6] E. Ko, H.W. Seo, G. Jung, Telomere length and ROS levels are positively associated with a high risk of mortality and recurrence in hepatocellular carcinoma, Hepatology 67 (4) (2018) 1378–1391.
[7] J.Y. Min, S.O. Lim, G. Jung, Downregulation of catalase by reactive oxygen species via hypermethylation of CpG island II on the catalase promoter, FEBS Lett. 584 (2010) 2427–2432.
[8] M. Gallardo, M.J. Hornbaker, X. Zhang, P. Hu, C. Bueso-Ramos, S.M. Post, Aberrant hnRNP K expression: all roads lead to cancer, Cell Cycle 15 (2016) 1552–1557.
[9] K. Bomzytky, O. Denisenko, J. Ostrowski, K. hnrNp: One protein multiple processes, Bioessays 26 (2004) 629–638.
[10] L.P. Ford, W.E. Wright, J.W. Shay, A model for heterogeneous nuclear ribonucleoproteins in telomere and telomerase regulation, Oncogene 21 (2002) 580–583.
[11] E. Ko, H.W. Seo, E.S. Jung, S.J. Seo, D.H. Kim, H. Cho, Y.J. Kim, Y.M. Park, J.S. Kim, G. Jung, PI3KDelta is a new therapeutic target in hepatocellular carcinoma, Hepatology 68 (6) (2018) 2285–2300.
[12] Q. He, P. Zeng, J.H. Tan, H.W. Seo, Y. Chang, J.A. Kang, S.G. Park, G. Jung, Oxidative modified PDIA3 promotes DKC1-mediated malignancy and survival of hepatocellular carcinoma cells, Hepatology 68 (5) (2018) 1851–1864.
[13] F.P. Barthel, W. Wei, M. Tang, E. Martinez-Ledesma, X. Hu, S.B. Amin, K.C. Akdemir, S. Seth, X.Z. Song, Q.H. Wang, T. Lichtenberg, J. Hu, J.H. Zhang, S.Y. Zheng, R.G.W. Verhaak, Systematic analysis of telomere length and somatic alterations in 31 cancer types, Nat. Genet. 49 (2017) 349–357.
[14] R.R. Reddel, Telomere maintenance mechanisms in cancer: clinical implications, Curr. Pharmaceut. Des. 20 (2014) 6363–6374.
[15] T.B. Gaspar, A. Sa, J.M. Lopes, M. Sobrinho-Simoes, P. Soares, J. Vinagre, Telomere maintenance mechanisms in cancer, Genes (2018) 9.
[16] Q. He, P. Zeng, J.H. Tan, T. Gu, L.Q. Guo, Z.S. Huang, D. Li, G-quadruplex-mediated regulation of telomere binding and survival of hepatocellular carcinoma cells, Gastroenterology 155 (2018) 748–760.
[17] W. Droge, Free radicals in the physiological control of cell function, Physiol. Rev. 82 (2002) 47–95.
[18] T. Grune, T. Reinheckel, K.J. Davies, Degradation of oxidized proteins in mammalian cells, FASEB J. 11 (1997) 526–534.
[19] M. Valko, D. Leibfritz, J. Moncol, M.T. Cronin, M. Mazur, J. Telser, Free radicals and antioxidants in normal physiological functions and human disease, Int. J. Biochem. Cell Biol. 39 (2007) 44–94.
[20] R. Gopalakrishna, S. Jaken, Protein kinase C signaling and oxidative stress, Free Radic. Biol. Med. 28 (2000) 1349–1361.
[21] C.R. Lee, K.S. Yang, J. Kwon, C. Lee, W. Jeong, S.G. Rhee, Reversible inactivation of...
the tumor suppressor PTEN by H2O2, J. Biol. Chem. 277 (2002) 20336–20342.

[22] R. Schreck, P.A. Baerele, A role for oxygen radicals as second messengers, Trends Cell Biol. 1 (1991) 39–42.

[23] S. Kage, N. Jones, A. Nomoto, Regulation of yAP-1 nuclear localization in response to oxidative stress, EMBO J. 16 (1997) 1710–1720.

[24] Z. Guo, S. Kozlov, M.F. Lavin, M.D. Person, T.T. Paull, ATM activation by oxidative stress, Science 330 (2010) 517–521.

[25] T.H. Robert, J. Hejgaard, N.F. Saunders, R. Cavicchioli, P.M. Curmi, Serpins in unicellular Eukarya, Archaea, and Bacteria: sequence analysis and evolution, J. Mol. Evol. 59 (2004) 437–447.

[26] S. Hutchinson, L.Y. Luo, G.M. Yousef, A. Soosaipillai, E.P. Diamandis, Purification of human kallikrein 6 from biological fluids and identification of its complex with alpha(1)-antichymotrypsin, Clin. Chem. 49 (2003) 746–751.

[27] B. Kroczynska, C.M. Evangelista, S.S. Samant, E.C. Elguindi, S.Y. Blond, The SANT2 domain of the murine tumor cell DnaJ-like protein 1 human homologue interacts with alpha1-antichymotrypsin and kinetically interferes with its serpin inhibitory activity, J. Biol. Chem. 279 (2004) 11432–11443.

[28] E.L. Huttlin, L. Ting, R.J. Bruckner, F. Gebreab, M.P. Gygi, J. Szpyt, G. Zarraga, G. Chen, J. Tie, Y. Cheng, G. Wang, S. Wan, D. Fang, POT1 deficiency alters telomere length and telomere-associated gene expression in human gastric cancer cells, Eur. J. Cancer Prev. 19 (2010) 345–351.

[29] T.N. Patel, R. Vasan, D. Gupta, J. Patel, M. Trivedi, Shelterin proteins and cancer, Asian Pac. J. Cancer Prev. APJCP 16 (2015) 3085–3090.

[30] H. Kim, J.E. Yoo, J.Y. Cho, B.K. Oh, Y.S. Yoon, H.S. Han, H.S. Lee, J.J. Jang, S.H. Jeong, J.W. Kim, Y.N. Park, Telomere length, TERT and shelterin complex proteins in hepatocellular carcinomas expressing 'stemness'-related markers, J. Hepatol. 59 (2013) 746–752.

[31] J.A. Irving, P.J. Steenbakkers, A.M. Lesk, H.J. Opden Camp, R.N. Pike, J.C. Whisstock, Serpins in prokaryotes, Mol. Biol. Evol. 19 (2002) 1881–1890.

[32] E. Lazzerini-Denchi, A. Sfeir, Stopping my strings – what telomeres taught us about the DNA damage response, Nat. Rev. Mol. Cell Biol. 17 (2016) 364–378.